Additives (e.g., Buffers, Diluents, Preservatives) Patents (Class 436/826)
  • Patent number: 8945360
    Abstract: Polyacrylamide gels that offer high resolution as electrophoretic media for protein separations and an improved resistance to hydrolysis upon storage are made by including either taurine, asparagine, or both as an ampholyte, in combination with either tris(hydroxymethyl)-aminomethane or bis(2-hydroxyethyl)amino-tris(hydroxymethyl)methane as a buffer, plus other conventional components.
    Type: Grant
    Filed: January 21, 2010
    Date of Patent: February 3, 2015
    Assignee: Bio-Rad Laboratories, Inc.
    Inventors: Shane Petersen, Cory Panattoni, Craig Rowell
  • Patent number: 7935541
    Abstract: An object of the present invention is to overcome the problem of nonspecific adsorption of a labeled antibody on the detection site and to provide an immunochromatography method by which the false positive signal can be suppressed, and wherein the detection sensitivity is high and the highly reliable measurement can be performed.
    Type: Grant
    Filed: September 26, 2008
    Date of Patent: May 3, 2011
    Assignee: Fujifilm Corporation
    Inventor: Hiroyuki Chiku
  • Patent number: 7482162
    Abstract: We disclose methods for measuring vitamin D metabolite in plasma or serum samples. The methods comprise a step of adding to the plasma or serum samples a non-competitive displacement agent comprising 8-anilino-1-naphthalenesulfonic acid ammonium salt, 3-(acetonylbenzyl)-4-hydroxycoumarin and a water miscible solvent. The non-competitive displacement agent separates vitamin D metabolite from binding proteins in the sample, such that the displaced vitamin D metabolite is available for capture and detection in subsequent binding assays. Thus, our invention finds use in methods of separating and detecting vitamin D metabolites otherwise tightly bound to plasma or serum binding proteins.
    Type: Grant
    Filed: December 6, 2001
    Date of Patent: January 27, 2009
    Assignee: Immunodiagnostic Systems Ltd.
    Inventors: David Laurie, Alexander Kirkley Barnes, Michael James Gardner
  • Patent number: 6951727
    Abstract: Improved methods, reagents, and kits for quantitation of HLA-DR and/or CD11b expression on peripheral blood cells are presented. Inclusion of a lysosomotropic amine, such as chloroquine, during staining stabilizes HLA-DR and CD11b expression. Use of a novel anti-CD14 conjugate, anti-CD14-PerCP/CY5.5, permits the ready discrimination of monocytes. The improved methods, reagents, and kits may be used to assess immune competence, and to direct and monitor immunostimulatory therapies in septic patients exhibiting monocyte deactivation.
    Type: Grant
    Filed: February 22, 2002
    Date of Patent: October 4, 2005
    Assignee: Becton Dickinson and Company
    Inventor: Kenneth A. Davis
  • Patent number: 6927071
    Abstract: A particle-enhanced assay for determining an analyte in a test sample in which an additive for reducing non-specific particle aggregation is added in an amount to substantially reduce non-specific aggregation. The additive is selected form the group consisting of triethanolamine, trimethanolamine, N-butyldiethanolamine, 3-dimethylamino-2-methylpropyl chloride, N,N-dimethylglycine, N,N-dimethylguanidine, N,N-dimethylglycine ethyl ester, 3-dimethylaminopropionitrile, and N,N-dietylacetamide.
    Type: Grant
    Filed: December 7, 2001
    Date of Patent: August 9, 2005
    Assignee: Beckman Coulter, Inc.
    Inventors: Kurt L. Brillhart, Julie A. Whiteside
  • Patent number: 6905886
    Abstract: This invention relates to preservative solutions for peptides, for example, parathyroid hormone, insulin-like growth factor binding protein 3 (IGFBP3), adrenocorticotropic hormone (ACTH) and mixtures thereof. Preferably, the peptides preserved by the solutions are non-reconstituted. In one embodiment, the preservative solutions comprise a polyvinyl alcohol, EDTA component and molybdic component.
    Type: Grant
    Filed: March 13, 2002
    Date of Patent: June 14, 2005
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Lata Sundaram, Ann Hoang, Stan Shimizu, Elizabeth R. Umelo-Njaka, Darcy A. Thomas
  • Patent number: 6890765
    Abstract: A method of treating particles to be used in immunoassays reduces interference in particle agglutination assays. For particles having covalently bound antibodies and residual NHS-ester or sNHS-ester groups on the surface, the reactive esters are treated with an aqueous mixture containing an amine compound of formula (I): H2N—R—X??(I). The moiety —X is —NH2, —OH, or —CO2CH2CH3; and R is an alkyl group or an alkyl ether group. When —X is —NH2 or —CO2CH2CH3, R contains from 1 to 20 carbon atoms; and when —X is —OH, R contains from 4 to 20 carbon atoms.
    Type: Grant
    Filed: December 18, 2001
    Date of Patent: May 10, 2005
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Christopher C. Lawrence, Wei Yuan, Armen B. Shanafelt
  • Patent number: 6777246
    Abstract: A reagent for use in immunoassays reduces interference in particle agglutination assays. The reagent contains particles having covalently bound antibodies and a tertiary amine compound of formula (I): N(R1—X)(R2—Y)(R3—Z)  (I). The moieties R1, R2, and R3 are independently alkyl or alkyl ether. The moieties X, Y, and Z are independently —OH, —O—R4, —S—R4, —C(═O)—OH, —C(═O)—OR4, or —C(═O)—NHR4 (R4 is alkyl).
    Type: Grant
    Filed: December 18, 2001
    Date of Patent: August 17, 2004
    Assignee: Roche Diagnostics GmbH
    Inventors: Christopher C. Lawrence, Armen B. Shanafelt
  • Patent number: 6767708
    Abstract: Aqueous solutions of steroid compounds which have biological activity and have a tendency to oxidative degradation at temperatures between 2 and 8° C. on storage in excess of several months are stabilized by the addition of chelators. Aqueous solutions of particular interest are protein containing solutions which mimic the behavior of human bodily fluids such as serum and are therefore suitable as standards for immunoassays for steroids in such bodily fluids. Chelators of particular interest are transition metal chelators especially those which efficiently sequester iron.
    Type: Grant
    Filed: December 8, 1995
    Date of Patent: July 27, 2004
    Assignee: Abbott Laboratories
    Inventors: Gregg T. Williams, Hoda I. Aboleneen, William R. Groskopf, Steven C. Kuemmerle
  • Patent number: 6740527
    Abstract: Cyanide-free reagents for the determination of hemoglobin and leukocytes present in a blood sample comprise an aqueous solutions of at least one quaternary ammonium salt, preferably selected from the group of alkyltrimethylammonium salts, alkyldimethylbenzylammonium salts or alkylpyridium salts consisting of tetradecyltrimethyl ammonium bromide (TTAB), dodecyltrimethyl ammonium chloride, cetyltrimethyl ammonium bromide, hexadecyltrimethyl ammonium bromide and benzalkonium chlorides, and hydroxylamine salts, especially hydrochloride, sulfate and phosphates and other acid salts. The method involves mixing the reagent with a diluent-diluted blood sample, presenting it to an absorbance spectrophotometer and measuring the resulting optical density as an indicator of hemoglobin concentration. This cyanide-free reagent could be used solely for hemoglobin determinations, or, it can also be used in leukocyte counting and sizing using hematology instrumentation.
    Type: Grant
    Filed: May 27, 1997
    Date of Patent: May 25, 2004
    Assignee: Abbott Laboratories
    Inventors: Show-Chu Wong, Sylvia Khoo
  • Patent number: 6706486
    Abstract: The present invention relates to a method for the quantitative release of natural or recombinant proteins, polypeptides (thermostable immunoligands) able to bind to the Fc-part of immunoglobulins (antibodies, in particular of the IgG class and primarily becoming bound outside the paratope) from complexes in various sample matrixes in order to make these released natural or recombinant proteins, polypeptides or peptides quantitatively available in immunochemical assays and to keep them quantitatively available. The method is characterized by mixing the sample with reagent compound that is able to bind non-specifically to immunoglobulins, and thereafter subjecting the sample to a heat treatment step followed by a cooling step.
    Type: Grant
    Filed: February 15, 2001
    Date of Patent: March 16, 2004
    Assignee: Amersham Biosciences AB
    Inventor: Franz Steindl
  • Patent number: 6620628
    Abstract: An assay element for analyzing a charged analyte employs an immobilized receptor and a material having a net charge which is the same as that of the analyte. In a preferred embodiment, the analyte is an aminoglycoside and the material is a polymer having a net positive charge.
    Type: Grant
    Filed: March 2, 2001
    Date of Patent: September 16, 2003
    Assignee: Ortho-Clinical Diagnostics, Inc.
    Inventors: Richard Sutton, Susan Danielson, Jerome Swartz, Linda Mauck
  • Publication number: 20030113794
    Abstract: A particle-enhanced assay for determining an analyte in a test sample in which an additive for reducing non-specific particle aggregation is added in an amount to substantially reduce non-specific aggregation.
    Type: Application
    Filed: December 7, 2001
    Publication date: June 19, 2003
    Inventors: Kurt L. Brillhart, Julie A. Whiteside
  • Patent number: 6579688
    Abstract: Compositions for stabilizing polypeptides or antigens are described. These compositions are useful for stabilizing polypeptides or antigens stored in aqueous formulations. Such formulations can be used for various analytical or other methods.
    Type: Grant
    Filed: December 14, 2000
    Date of Patent: June 17, 2003
    Assignee: Biostar, Inc.
    Inventors: Jeffrey W. Steaffens, Laura Panzarella
  • Patent number: 6500629
    Abstract: The subject invention pertains to methods and materials for accurately assessing the presence or absence of analytes of interest in samples, particularly in physiological samples. The subject invention involves utilizing a ligand binding domain (LBD) of a receptor to selectively capture the analyte target specific for that LBD. In one embodiment, the receptor is a protein or polypeptide. The ligand binding domain is allowed to react with a sample and the presence or amount of ligand (i.e., target analyte) bound by the LBD is determined. Suitable analytes include soluble analytes such as hormones, enzymes, lipoproteins, bacterial or viral antigens, immunoglobulines, lymphokines, cytokines, drugs, soluble cancer antigens, and the like. The methods of the present invention can be performed in both liquid-phase and solid-phase.
    Type: Grant
    Filed: September 13, 2000
    Date of Patent: December 31, 2002
    Assignee: Equitech Laboratories, Inc.
    Inventors: Brian D. Cleaver, Mike L. Green
  • Patent number: 6338960
    Abstract: Histamine may be quantitatively measured by performing the following steps. First, an oocyte that expresses histamine receptors is held in a recess formed at the bottom of a vessel. Then, first and second electrodes are inserted into the oocyte. Subsequently, the membrane potential of the oocyte is measured by using the first electrode to stabilize this membrane potential at a predetermined level by driving a current through the second electrode using circuitry for clamping the membrane potential of the oocyte. A sample is then infused into a fine reacting tube having an antigen immobilized on its inner surface together with some buffer solution to promote a histamine releasing reaction. The solution containing histamines that is released in the fine reacting tube is transferred to the vessel to make contact with the oocyte in the vessel.
    Type: Grant
    Filed: February 21, 2001
    Date of Patent: January 15, 2002
    Assignee: Hitachi, Ltd.
    Inventors: Tomoko Takeshita, Jun Otomo
  • Patent number: 6337178
    Abstract: Histamine may be quantitatively measured by performing the following steps. First, an oocyte that expresses histamine receptors is held in a recess formed at the bottom of a vessel. Then, first and second electrodes are inserted into the oocyte. Subsequently, the membrane potential of the oocyte is measured by using the first electrode to stabilize this membrane potential at a predetermined level by driving a current through the second electrode using circuitry for clamping the membrane potential of the oocyte. A sample is then infused into a fine reacting tube having an antigen immobilized on its inner surface together with some buffer solution to promote a histamine releasing reaction. The solution containing histamines that is released in the fine reacting tube is transferred to the vessel to make contact with the oocyte in the vessel.
    Type: Grant
    Filed: April 30, 2001
    Date of Patent: January 8, 2002
    Assignee: Hitachi, Ltd.
    Inventors: Tomoko Takeshita, Jun Otomo
  • Patent number: 6277559
    Abstract: Histamine may be quantitatively measured by performing the following steps. First, an oocyte that expresses histamine receptors is held in a recess formed at the bottom of a vessel. Then, first and second electrodes are inserted into the oocyte. Subsequently, the membrane potential of the oocyte is measured by using the first electrode to stabilize this membrane potential at a predetermined level by driving a current through the second electrode using circuitry for clamping the membrane potential of the oocyte. A sample is then infused into a fine reacting tube having an antigen immobilized on its inner surface together with some buffer solution to promote a histamine releasing reaction. The solution containing histamines that is released in the fine reacting tube is transferred to the vessel to make contact with the oocyte in the vessel.
    Type: Grant
    Filed: February 21, 2001
    Date of Patent: August 21, 2001
    Assignee: Hitachi, Ltd.
    Inventors: Tomoko Takeshita, Jun Otomo
  • Patent number: 6177283
    Abstract: For blood or other physiological fluid sample collection kits that use filter paper to collect the sample, the performance of the kit and associated analytical method can be improved by using a material having properties which are superior to those of standard filter paper or modified filter paper routinely used in standard biological assays. Certain materials currently available for uses other than blood collection, storage, or transport have properties that are advantageous as employed in assays of biological fluids, including the use of specific cellulose blotting materials for collecting blood samples for hemoglobin or hemoglobin A1c monitoring.
    Type: Grant
    Filed: May 28, 1998
    Date of Patent: January 23, 2001
    Assignee: FlexSite Diagnostics, Inc.
    Inventor: Robert A. Ray
  • Patent number: 6143537
    Abstract: A method for stabilizing analyses with antibodies and antibody fragments comprises dissolving the analyte in a liquid to form a solution, adding analyte-specific antibodies, fragments of such antibodies, or both to the solution, heating the solution, and then cooling and filtering the solution. The filtered solution may be diluted in a suitable matrix.
    Type: Grant
    Filed: January 5, 1999
    Date of Patent: November 7, 2000
    Assignee: Medical Analysis Systems, Inc.
    Inventors: Shing F. Kwan, Ivan E. Modrovich, Rebecca J. Hunt
  • Patent number: 6103538
    Abstract: Disclosed herein is a method for the detection of a target substance by a colloidal gold immunoassay, which comprises dissolving in an immunoreaction system a metal salt selected from the group consisting of sodium, potassium and lithium fluorides, sodium, potassium, lithium and magnesium iodides, sodium, potassium, lithium and magnesium bromides, lithium and magnesium chlorides, sodium, potassium, lithium and magnesium nitrates, sodium, potassium, lithium and magnesium sulfates, sodium, potassium, lithium and magnesium formates, sodium, potassium, lithium and magnesium acetates, and mixtures of at least two of these metal salts, whereby the metal salt is allowed to exist in a reaction mixture.
    Type: Grant
    Filed: December 22, 1997
    Date of Patent: August 15, 2000
    Assignee: SS Pharmaceutical Co., Ltd.
    Inventor: Takeshi Kotsugai
  • Patent number: 6096508
    Abstract: This invention relates to an improvement in a method for detecting labeled molecules and especially biotinylated molecules and particularly relates to a method for reducing background signal problems in such detection methods.
    Type: Grant
    Filed: August 16, 1995
    Date of Patent: August 1, 2000
    Assignee: Kirkegaard & Perry Laboratoies, Inc.
    Inventors: Michael S. Lemar, Katherine MacLean Peterson, Carrington S. Cobbs
  • Patent number: 6083530
    Abstract: A method for encapsulation of antineoplastic agents in liposomes is provided, having preferably a high drug:lipid ratio. Liposomes may be made by a process that loads the drug by an active mechanism using a transmembrane ion gradient, preferably a transmembrane pH gradient. Using this technique, trapping efficiencies approach 100%, and liposomes may be loaded with drug immediately prior to use, eliminating stability problems related to drug retention in the liposomes. Drug:lipid ratios employed are about 3-80 fold higher than for traditional liposome preparations, and the release rate of the drug from the liposomes is reduced. An assay method to determine free antineoplastic agents in a liposome preparation is also disclosed.
    Type: Grant
    Filed: May 26, 1998
    Date of Patent: July 4, 2000
    Assignee: The Liposome Company, Inc.
    Inventors: Lawrence D. Mayer, Marcel B. Bally, Pieter R. Cullis, Richard S. Ginsberg, George N. Mitilenes
  • Patent number: 6080385
    Abstract: Disclosed are methods for measuring non-contractile oxidative metabolism in smooth muscle cells comprising providing a medium suitable for the support of oxidative metabolism, incubating a cell or tissue sample with a specimen from a patient, measuring a marker of oxidative metabolism in the incubate, and detecting an increase in oxidative metabolism which is not attributable to a contractile demand for ATP. Such an increase in oxidative metabolism will be indicative of the existence of an agent or combination of agents able to cause an increase in oxidative metabolism in smooth muscle cells, and thus provides means for diagnosing and monitoring various pathologies associated therewith.
    Type: Grant
    Filed: October 19, 1998
    Date of Patent: June 27, 2000
    Assignee: Medical Research Council
    Inventors: Joseph F. Clark, Thomas A. D. Cadoux-Hudson
  • Patent number: 6077518
    Abstract: Isolated allergens of Dermatophagoides (house dust mites) particularly of the species and Dermatophagoides pteronyssinus, which are protein allergens or peptides which include at least one epitope of the protein allergen. In addition, the or peptides encoded by the isolated DNA, their use as diagnostic and therapeutic reagents and methods of diagnosing and treating sensitivity to house dust mite allergens.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: June 20, 2000
    Assignee: ImmuLogic Pharmaceutical Corporation
    Inventors: Wayne Robert Thomas, Geoffrey Alexander Stewart, Keven Turner, Richard John Simpson
  • Patent number: 5858805
    Abstract: This invention is directed to the use of polycarboxylic acid polymers to enhance the performance of immunochemical assays for the quantitation of aminoglycoside antibiotics in biological samples. This invention is also concerned with the improved homogeneous, immunochemical detection assays resulting from the use of said polycarboxylic acid polymers in said assays.
    Type: Grant
    Filed: January 13, 1997
    Date of Patent: January 12, 1999
    Assignee: Roche Diagnostic Systems, Inc.
    Inventor: Charles Minnan Cheng
  • Patent number: 5837474
    Abstract: A method of detecting malignant tumors and determining their mass includes withdrawing fresh blood and/or serum samples from the patient. The blood or serum sample is then stabilized. The tumor determination is obtained from a shift in the ratio of at least one of the IgG subclasses to the sum of the IgG subclasses, relative to the normal ratio in the samples.
    Type: Grant
    Filed: January 30, 1995
    Date of Patent: November 17, 1998
    Inventors: Erwin Schauenstein, Konrad Schauenstein, Franz Dachs
  • Patent number: 5795589
    Abstract: A method for encapsulation of antineoplastic agents in liposomes is provided, having preferably a high drug:lipid ratio. Liposomes may be made by a process that loads the drug by an active mechanism using a transmembrane ion gradient, preferably a tranamembrane pH gradient. Using this technique, trapping efficiencies approach 100%, and liposomes may be loaded with drug immediately prior to use, eliminating stability problem related to drug retention in the liposomes. Drug:lipid ratios employed are about 3-80 fold higher than for traditional liposome preparations, and the release rate of the drug from the liposomes is reduced. An assay method to determine free antineoplastic agents in a liposome preparation is also disclosed.
    Type: Grant
    Filed: February 5, 1997
    Date of Patent: August 18, 1998
    Assignee: The Liposome Company, Inc.
    Inventors: Lawrence D. Mayer, Marcel B. Bally, Pieter R. Cullis, Richard S. Ginsberg, George N. Mitilenes
  • Patent number: 5773304
    Abstract: A method for quantitatively determining cholesterol in high density lipoproteins, in which, prior to the determination of cholesterol by an enzymatic method, a surfactant and a substance which forms a complex with lipoproteins other than high density lipoproteins are added to a sample containing lipoproteins.The method does not require any pretreatments such as centrifugal separation. With a simple operation, cholesterol in HDLs can be measured effectively. Also, this method can be adopted in a variety of automated analyzers, and thus is very useful in the field of clinical assays.
    Type: Grant
    Filed: September 19, 1996
    Date of Patent: June 30, 1998
    Assignee: Daiichi Pure Chemicals Co., Ltd.
    Inventors: Koichi Hino, Mitsuhiro Nakamura, Mitsuhisa Manabe
  • Patent number: 5731157
    Abstract: An allergen immunoassay method features the use of a combination of a) closely controlled 1) elevated temperatures for assay reactions, 2) low temperatures for reagents and samples, 3) times for assay steps and especially assay reaction times, 4) reagent concentrations, and 5) reagent amounts; b) the use of a fast and accurate method of sample preparation that removes dust and contaminants; c) the stabilization of samples to avoid auto- and antibody degradation and unwanted effects of sample contaminants; and d) the formation of a colored product to determine the amount of a specific allergen. This combination provides an assay that can be completed in a few hours while retaining the precision, accuracy, sensitivity and response curve of previous methods requiring much longer periods of time.
    Type: Grant
    Filed: December 30, 1993
    Date of Patent: March 24, 1998
    Assignee: The Procter and Gamble Company
    Inventors: Larry S. Miller, Balwant S. Bhullar, Richard S. Tuttle, Victor S. Moore
  • Patent number: 5691150
    Abstract: Described are immunoassay of insulin-like growth factors in a biological sample, which comprises prior to the immunoassay, treating the biological sample with an acid solution to liberate the insulin-like growth factors from insulin-like growth factor binding proteins and then neutralizing the so-treated biological sample with a neutralizing buffer containing a recombination inhibitor; and immunoassay kit for insulin-like growth factors.
    Type: Grant
    Filed: November 9, 1995
    Date of Patent: November 25, 1997
    Assignee: Daiichi Radioisotope Laboratories, Ltd.
    Inventors: Kazumine Mori, Shigeto Takasu, Hiroyuki Kasahara, Shuji Horikawa
  • Patent number: 5686316
    Abstract: The invention is a rapid, continuous test for glycated hemoglobin using a non-equilibrium affinity binding method. Agarose beads derivatized with 3-aminophenylboronic acid specifically bind glycated hemoglobin. This solid phase is incorporated into a sample processor card, modified to mix and to separate the test solution from the solid phase prior to absorbance readings. Two absorbance readings are made on the test solution, one immediately after mixing the reagent/diluent with the specimen, and one after a significant amount of binding has occurred. A linear correlation between total glycated hemoglobin and hemoglobin A.sub.1c permits standardization and reporting of units equivalent to % hemoglobin A.sub.1c. Stable glycated hemoglobin solutions for use as standards in the assay, and a method for preparing the standards are also disclosed.
    Type: Grant
    Filed: April 28, 1995
    Date of Patent: November 11, 1997
    Assignee: Abbott Laboratories
    Inventors: Michael D. Fiechtner, John M. Ramp, Barbara J. England, Mary J. Annino
  • Patent number: 5679536
    Abstract: A chemiluminescent method is provided for the analysis of a target. A peroxidase is first bound as a labelling substance to the target by using a target specific binding reagent. The target so labelled is isolated and then reacted with luminol, hydrogen peroxide and an enhancer in an aqueous solvent. The luminescence of light is detected and measured. The aqueous solvent contains at least one protein selected from the group consisting of skim milk and egg albumin. Preferably, the aqueous solvent also contains a non-ionic surfactant such as a polyoxyethylene ether and/or a sugar alcohol such as mannitol.
    Type: Grant
    Filed: July 19, 1995
    Date of Patent: October 21, 1997
    Assignee: Hitachi Chemical Co. Ltd.
    Inventors: Takashi Hayashi, Riko Iwata, Mitsuo Yamaki
  • Patent number: 5660978
    Abstract: A method for stabilizing analytes with antibodies and antibody fragments comprises dissolving the analyte in a liquid to form a solution, adding analyte-specific antibodies, fragments of such antibodies, or both to the solution, heating the solution, and then cooling and filtering the solution. The filtered solution may be diluted in a suitable matrix.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: August 26, 1997
    Assignee: Ivan E. Modrovich
    Inventors: Shing Fai Kwan, Ivan E. Modrovich, Rebecca Jolene Hunt
  • Patent number: 5658737
    Abstract: The invention relates to methods for simultaneously or sequentially detecting multiple nucleic acid analytes in a single medium utilizing oligonucleotide hybridization probes coupled to different chemiluminescent labeling reagents. The methods may be used in a heterogeneous, homogeneous or non-homogeneous assay system. The invention also relates to specific combinations of chemiluminescent labeling reagents suitable, when coupled to an oligonucleotide probe, for use together in methods for the detection of multiple nucleic acid analytes. The invention also concerns kits useful in these methods.
    Type: Grant
    Filed: August 6, 1996
    Date of Patent: August 19, 1997
    Assignee: Gen-Probe Incorporated
    Inventors: Norman Charles Nelson, James Stuart Woodhead, Ian Weeks, Azzouz Ben Cheikh
  • Patent number: 5648222
    Abstract: This invention provides a method for preserving cells which comprises the steps of (a) suspending cells in a physiologically-acceptable, isotonic medium; and (b) fixing the cells so suspended at a temperature of less than about 10.degree. C. under sufficiently hypertonic conditions so as to disperse the cells in a single, unagglutinated state, thereby preserving cells. This invention also provides a method for detecting cells separated from a sample which have been preserved according to the aforementioned method. This invention also provides a method for visualizing cells. Also provided is a method for detecting a metabolic process in cells present in a sample. This invention also provides a method for detecting the presence of rare cells in a sample which specifically possess on their surfaces a moiety recognized by a known ligand comprising preserving cells separated from the sample according to the aforementioned method for preserving cells.
    Type: Grant
    Filed: July 27, 1994
    Date of Patent: July 15, 1997
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Doris B. Tse, Hui-Min Chung, Leonardus H. T. Van der Ploeg
  • Patent number: 5641637
    Abstract: A method is disclosed for preparing lyophilized and frozen cells as cytometry standards.
    Type: Grant
    Filed: April 5, 1993
    Date of Patent: June 24, 1997
    Assignee: Cobe Laboratories, Inc.
    Inventors: Robert Hudak, Iris Williams, Vijay Adda, Raymond P. Goodrich, Jr.
  • Patent number: 5637509
    Abstract: Method for a homogeneous biospecific affinity assay for determining the content of a substance (analyte) in a biological sample. The assay is carried out in an aqueous reaction medium by means of time-resolved fluorescence spectroscopy and with a biospecific affinity reactant labeled with a lanthanide chelate in which a lanthanide ion exhibiting ionic fluorescence is chelated by a ligand bound covalently to the reactant. The characteristic feature is(i) that the lanthanide chelate formed by the lanthanide ion together with the covalently bound ligand forms a fluorescent chelate, and(ii) that a modulator is added which stabilizes the lanthanide chelate so that the lanthanide fluorescence as measured from the medium becomes a practically pure function of the analyte concentration therein.
    Type: Grant
    Filed: December 12, 1990
    Date of Patent: June 10, 1997
    Assignee: Wallac Oy
    Inventors: Ilkka Hemmila, Timo Lovgren
  • Patent number: 5627080
    Abstract: Methods for modulating the rates and dose responses of immunoassays through the incorporation of one or more detergents into the immunoassay reaction are disclosed. The methods are particularly suitable for automated immunoassay formats, especially with formats that use analyte-biotin bidentate reagents. The methods may be used to facilitate the detection of any desired, preselected pharmacological agent.
    Type: Grant
    Filed: July 29, 1994
    Date of Patent: May 6, 1997
    Assignee: Beckman Instruments, Inc.
    Inventors: Anthony K. Cheng, Julie S. Kim, Chan S. Oh
  • Patent number: 5616460
    Abstract: An aqueous composition suitable for use when performing immunological procedures. The composition includes at least one biological buffer, dithiothreitol (alternatively referred to herein as "DTT"), and ethylene glycol. The composition can also include at least one biological detergent, at least one source of positive and negative counterions, e.g., salt, and at least one viscosity modifier, e.g., sugar. The buffer also can include at least one preservative, such as sodium azide. The pH of the composition preferably ranges from about 6.4 to 7.2. A kit containing the composition is also disclosed.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: April 1, 1997
    Assignee: Abbott Laboratories
    Inventor: Steve D. Figard
  • Patent number: 5589393
    Abstract: The invention is a rapid, continuous test for glycated hemoglobin using a non-equilibrium affinity binding method. Agarose beads derivatized with 3-aminophenylboronic acid specifically bind glycated hemoglobin. This solid phase is incorporated into a sample processor card, modified to mix and to separate the test solution from the solid phase prior to absorbance readings. Two absorbance readings are made on the test solution, one immediately after mixing the reagent/diluent with the specimen, and one after a significant amount of binding has occurred. A linear correlation between total glycated hemoglobin and hemoglobin A.sub.1c permits standardization and reporting of units equivalent to % hemoglobin A.sub.1c. Stable glycated hemoglobin solutions for use as standards in the assay, and a method for preparing the standards are also disclosed.
    Type: Grant
    Filed: April 24, 1995
    Date of Patent: December 31, 1996
    Assignee: Abbott Laboratories
    Inventors: Michael D. Fiechtner, John M. Ramp, Barbara J. England, Mary J. Annino
  • Patent number: 5585246
    Abstract: An assay and sample mixture for the enumeration of fluorescently stained target components of a whole blood sample by an imaging instrument. The sample preparation method ensures that the amount of target components per unit of volume of the whole blood sample is preserved by elimination of certain non-quantitative preparation steps while producing an even hematocrit layer within a scan capillary. Typical target components include white blood cells that express certain surface antigens, such as CD-4 and CD-8 proteins. To inhibit aggregation of the red blood cells, a reagent is added to an aliquot of whole blood sample. The aliquot of whole blood is mixed and with a preselected amount of a fluorescent dye and ligand complex which tags the target components.
    Type: Grant
    Filed: October 24, 1994
    Date of Patent: December 17, 1996
    Assignee: Biometric Imaging, Inc.
    Inventors: Robert S. Dubrow, Bala S. Manian
  • Patent number: 5558996
    Abstract: A method and kit for extracting fungus from a plant. An extraction solution is combined with tissue from a plant and the combination is agitated, preferably by shaking, to extract a detectable amount of the fungus from the plant. The extraction solution is a solution containing a dilute acid and a detergent. The extract can then be neutralized without degradation of the fungus and subjected to analysis by immunoassay to detect the presence of pathogenic fungi. The method is particularly useful for the detection of Pyricularia oryzae on rice plants.
    Type: Grant
    Filed: July 1, 1994
    Date of Patent: September 24, 1996
    Assignee: Strategic Diagnostics Inc.
    Inventors: William C. Bartlett, James M. Melby
  • Patent number: 5552142
    Abstract: The present invention features isolated DNA encoding allergens of Dermatophagoides (house dust mites) particularly of the species Dermatophagoides farinae and Dermatophagoides pteronyssinus, which are protein allergens or peptides which include at least one epitope of the protein allergen. In particular, the invention provides DNA encoding the major D, farinae allergens, Der f I and Der f II and DNA encoding the major D. pteronyssinus allergens, Der p I and Der p II. The present invention further relates to proteins and peptides encoded by the isolated D. farinae and D. pteronyssinus DNA, including proteins containing sequence polymorphisms. In addition, the proteins or peptides encoded by the isolated DNA, their use a diagnostic and therapeutic reagents and methods of diagnosing and treating sensitivity to house dust mite allergens, are disclosed.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: September 3, 1996
    Assignee: Immulogic Pharmaceutical Corporation
    Inventors: Wayne R. Thomas, Kaw-Yan Chua
  • Patent number: 5541116
    Abstract: Method for the stabilisation of endogenous physiologically active peptides in human whole blood, serum and plasma samples before and/or during the determination of the-concentration of these peptides by immunodiagnostic or physical assay methods, in which a stabiliser combination which consists of the protease inhibitors amastatin and leupeptin and ethylenediaminetetraacetic acid (EDTA) or contains the stated compounds is added to the samples.
    Type: Grant
    Filed: October 1, 1993
    Date of Patent: July 30, 1996
    Assignee: B.R.A.H.M.S. Diagnostica GmbH
    Inventor: Andreas Bergmann
  • Patent number: 5514654
    Abstract: N-acyldipeptides of formula I ##STR1## wherein R represents a rest of formula ##STR2## and R.sub.4, Y, m, n and Z have the meaning as defined in the description, R.sub.1 represents hydrogen, a 1-10 C. alkyl, an optionally substituted methyl or benzyl,R.sub.2 represents a --CO--A group,wherein A has the meanings as defined in the description,R.sub.3 represents a --(CH.sub.2).sub.p --CO--W group,wherein p and W have the meaning as defined in the description.
    Type: Grant
    Filed: May 18, 1994
    Date of Patent: May 7, 1996
    Inventors: Slavko Pecar, Marija Sollner, Uros Urleb, Danijel Kikelj, Gasper Marc, Ales Krbavcic, Vlado Kotnik, Branka Wraber-Herzog, Sasa Simcic, Alojz Ihan, Lidija Klamfer, Lucka Povsic, Zdravko Kopitar, Anton Stalc
  • Patent number: 5506151
    Abstract: A non-specific reaction suppressor for immunoassays having the formula: ##STR1## where R.sub.1, R.sub.2, Y, X, and R.sub.3 are defined in the specification.
    Type: Grant
    Filed: February 9, 1994
    Date of Patent: April 9, 1996
    Assignee: Mitsubishi Kasei Corporation
    Inventors: Michio Ito, Satoshi Sugawa, Atsushi Yanagida
  • Patent number: 5506110
    Abstract: As a carrier for binding of the antiphospholipid antibodies used for immunological diagnosis of antiphospholipid syndrome, a phospholipid-bound carrier treated with purified serum albumin and a surfactant is used. Thus, immunological diagnosis of antiphospholipid syndrome can be made with high accuracy. By using the fraction or protein obtained from animal serum or plasma, having the activity of enhancing the binding ability of the antibodies specifically present in the antiphospholipid syndrome to the phospholipid, immunological diagnosis of antiphospholipid syndrome can also be made more accurately, as compared to known diagnosis.
    Type: Grant
    Filed: June 14, 1993
    Date of Patent: April 9, 1996
    Assignee: Yamasa Shoyu Kabushiki Kaisha
    Inventors: Eiji Matsuura, Yoshiko Igarashi, Hisato Nagae
  • Patent number: 5460944
    Abstract: The present invention provides a storable POD conjugate solution, characterised by a pH value of 5.0 to 6.5, adjusted by means of an organic buffer substance with a concentration of 40 to 100 mmol/l, and 0.05 to 1.0 mol/l magnesium aspartate.
    Type: Grant
    Filed: April 21, 1993
    Date of Patent: October 24, 1995
    Assignee: Boehringer Mannheim GmbH
    Inventors: Norbert Franken, Nicholas Hoyle, Gunter Pappert
  • Patent number: 5459033
    Abstract: The invention concerns a virus solution which contains a detergent having the general formula I and serves to stabilize the virus solution as well as its production and use in heterogeneous immunoassays for the detection of antibodies against viruses.
    Type: Grant
    Filed: April 2, 1993
    Date of Patent: October 17, 1995
    Assignee: Boehringer Mannheim GmbH
    Inventors: Heiner Vonwirth, Michael Marschall, Hubert Bayer